Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc. | Pelacarsen (TQJ230) (AKCEA-APO(a)-LRx) | Hyperlipoproteinemia(a) and established cardiovascular disease | Phase 3 | Ongoing | Subcutaneous | Cardiology |
| Ionis Pharmaceuticals Inc. | ION449 (AZD8233) - (SOLANO) | Hypercholesterolemia | Phase 2b | Trial Discontinued | Subcutaneous | Cardiology |
| Ionis Pharmaceuticals Inc. | Fesomersen (IONIS-FXI-LRx) - (RE-THINC) | End-stage renal disease (ESRD) | Phase 2b | Ongoing | Subcutaneous | N/A |
| Ionis Pharmaceuticals Inc. | ION224 | metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH) | Phase 2b | Ongoing | Oral | Gastroenterology |
| Ionis Pharmaceuticals Inc. | IONIS-AGT-LRx | Hypertension | Phase 2b | Ongoing | Subcutaneous | Cardiology |
| Ionis Pharmaceuticals Inc. | ION449 (AZD8233) - (ETESIAN) | Dyslipidaemia | Phase 2b | Data Released | Subcutaneous | Cardiology |
| Ionis Pharmaceuticals Inc. | Vupanorsen (AKCEA-ANGPTL3-LRx) - (TRANSLATE-TIMI 70) | Cardiovascular (CV) risk reduction and hypertriglyceridemia | Phase 2b | Subcutaneous | Cardiology | |
| Ionis Pharmaceuticals Inc. | IONIS-MAPTRx (ISIS 814907; BIIB080) - (CELIA) | Alzheimer's disease | Phase 2 | Data Released | Intrathecal | Neurology |
